October 15, 2024
1 min watch
Save
VIDEO: Data on neuroprotective agents for geographic atrophy discussed at ASRS
In this video, Barbara Blodi, MD, discusses early data on neuroprotective agents for the treatment of geographic atrophy.
In a phase 1b study presented during a dry AMD symposium at the ASRS meeting, the fatty acid synthase inhibitor ONL1204 (ONL Therapeutics) showed safety and tolerability.
In addition, Blodi discusses the phase 2/3 trial of AVD-104 (Aviceda Therapeutics) for geographic atrophy.
References:
- Borkar D, et al. Fas inhibition with ONL1204 for the treatment of geographic atrophy: First-time results from a phase 1b study. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
- Singh R, et al. Results from part 1 of the phase 2/3 SIGLEC trial assessing AVD-104 for geographic atrophy: Glyco-immunologic modulation of macrophage activity. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Blodi reports no relevant financial disclosures.
Read more about